Financial reports
ARS
2023 FY
Annual report to shareholders
26 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
Current reports
8-K
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
28 Mar 24
8-K
Daré Bioscience Announces Executive Team and Board of Directors Changes
26 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure $5 million at closing and up to $7 million of additional committed funding
26 Dec 23
8-K
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study
20 Dec 23
8-K
Changes in Registrant's Certifying Accountant
9 Nov 23
8-K
Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update
9 Nov 23
8-K
Regulation FD Disclosure
1 Nov 23
8-K
Regulation FD Disclosure
16 Oct 23
Registration and prospectus
S-3
Shelf registration
29 Mar 24
S-3
Shelf registration
29 Mar 24
424B5
Prospectus supplement for primary offering
28 Mar 24
D
$4.16 mm in options / securities to be acquired, sold $1.73 mm, 1 investor
26 Dec 23
424B5
Prospectus supplement for primary offering
30 Aug 23
424B5
Prospectus supplement for primary offering
31 Mar 23
S-8
Registration of securities for employees
9 Aug 22
S-8
Registration of securities for employees
31 Mar 22
424B5
Prospectus supplement for primary offering
13 Oct 21
D/A
$3.54M in equity, sold $3.54M, 28 investors
7 Sep 21
Proxies
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
PRE 14A
Preliminary proxy
16 Apr 24
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Jun 22
DEFA14A
Additional proxy soliciting materials
24 Jun 22
DEFA14A
Additional proxy soliciting materials
22 Jun 22
DEFA14A
Additional proxy soliciting materials
21 Jun 22
DEFA14A
Additional proxy soliciting materials
29 Apr 22
Other
EFFECT
Notice of effectiveness
8 Apr 21
CORRESP
Correspondence with SEC
5 Apr 21
UPLOAD
Letter from SEC
2 Apr 21
EFFECT
Notice of effectiveness
8 Jan 21
CORRESP
Correspondence with SEC
6 Jan 21
CORRESP
Correspondence with SEC
4 Jan 21
CORRESP
Correspondence with SEC
4 Jan 21
EFFECT
Notice of effectiveness
9 Jun 20
CORRESP
Correspondence with SEC
4 Jun 20
CORRESP
Correspondence with SEC
29 May 20
Ownership
4
John A Fair
14 Mar 24
4
SABRINA MARTUCCI JOHNSON
14 Mar 24
4
MarDee Haring-Layton
14 Mar 24
3
MarDee Haring-Layton
29 Jan 24
4
Cheryl R Blanchard
21 Jun 23
4
Jessica D. Grossman
21 Jun 23
4
Robin Joan Steele
21 Jun 23
4
Sophia Nnenna Ononye-Onyia
21 Jun 23
4
Susan L. Kelley
21 Jun 23
4
WILLIAM H RASTETTER
21 Jun 23